Market research

BMY Bristol-Myers Squibb Company

NYSE USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market cap: 137B
P/E ratio: 14.76
Analyst target: 66.2083
Dividend yield: 3.8%
Beta: 0.23

Loading price history…

Profile

Company facts

Exchange: NYSE
Currency: USD
Sector: Healthcare
Industry: Drug Manufacturers - General
ISIN: US1101221083
Market cap: 137B
P/E ratio: 14.76
Analyst target: 66.2083
Dividend yield: 3.8%
Beta: 0.23

About

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

Admin

5 years, 4 months ago

Bristol-Myers Squibb Company is currently in a long term uptrend where the price is trading 5.9% above its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.

Bristol-Myers Squibb Company's total revenue rose by 39.3% to $11B since the same quarter in the previous year.

Its net income has dropped by 849.5% to $-10B since the same quarter in the previous year.

Finally, its free cash flow grew by 89.5% to $3B since the same quarter in the previous year.

Based on the above factors, Bristol-Myers Squibb Company gets an overall score of 4/5.

shortputs

5 years, 7 months ago

@LiveTradePro @Rebooter In terms of future business prospects, $SDGR now vs June 2020 looks MUCH stronger. The $BMY deal was only announced in November. $55m will be paid upfront, of the $2.7b in milestone payments $BAC analyst thinks $1.6b is realistic/achievable as they are pre-clinical milestones expected to conclude within 4 years, and $SDGR will get royalties on top of that if drugs get commercialized. This 1 deal alone is huge for a company currently on a $100m revenue run rate and market cap at just $6b. Added to that their growing SaaS business that has been their bread and butter, other collab deals (incl one with $TAK) and other drug programs in pipeline that can be monetized into more deals like the $BMY one, this still has a lot of room to run for years imo.

Equity Stats

5 years, 7 months ago

S&P 500 stocks with lowest standard deviation of daily returns over the last year (as of 1/8/2021): 1. Verizon Communications $VZ (SD = 1.54%), 2. Costco Wholesale $COST (SD = 1.83%), 3. Bristol-Myers Squibb $BMY (SD = 1.86%), 4. Hormel Foods $HRL (SD = 1.9%), 5. Johnson & Johnson $JNJ (SD = 1.9%)

John

5 years, 7 months ago

$BMY to me next week is the big week, they options are calling for something big. A lot of puts as well but below are the calls. Something is coming.

TradeWithAlerts

5 years, 7 months ago

Large Print $BMY Size: 143277 Price: 62.19 Time: 930 Amount: $8,910,396.63

marc migs

5 years, 7 months ago

$SLS $BMY while I share your fervor about the data, the virtual conference starts on Monday.

Mike Mercker

5 years, 7 months ago

$BMY getting tired of this thing never moving out of for a long time collecting dividends that's about it

James Lawrence

5 years, 7 months ago

$BMY Jesus..... I could sell this, invest elsewhere and then come back in 2 years and buy again at $61.50. This pig never moves.

John

5 years, 7 months ago

$TSLA this thing meets price targets a week after getting them. Where I’m in $bmy and can’t meet one target for over a year.

John

5 years, 7 months ago

$BMY any option expert out there know why someone today would pick up 1700 100 call options and 1900 55 put options dated for next week? Both seem unrealistic. What am I missing.